An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients

BACKGROUND: Addition of erlotinib to metronomic chemotherapy (MCT) may lead to further improvement in progression-free survival (PFS) and overall survival in head and neck cancers. The aim of this study was to study the PFS with MCT + erlotinib combination in our setting. METHODS: A single-arm prosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Patil, Vijay M., Chakraborty, Santam, Jithin, T. K., Sajith Babu, T. P., Babu, Satheesh, Kumar, Shiva, Biji, M. S., Bhattacharjee, Atanu, Balasubramanian, Satheesan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
METRONOMIC THERAPY IN HEAD AND NECK CANCERS: Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873694/
https://www.ncbi.nlm.nih.gov/pubmed/27275445
http://dx.doi.org/10.4103/2278-330X.181624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873694/
https://www.ncbi.nlm.nih.gov/pubmed/27275445
http://dx.doi.org/10.4103/2278-330X.181624

Ejemplares similares